Early Phase 1 Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are willing to take part voluntarily, have been fully informed about the study, and have signed a consent form before any study-related procedures begin.
- People aged 18 or older.
- People whose general health and ability to carry out daily activities is rated as fully active or restricted only in physically strenuous activity (this is measured using a standard scale called the ECOG scale, scored 0 or 1).
- People who have at least one area of disease that can be measured on scans or tests.
- People whose multiple myeloma has come back after treatment or has stopped responding to treatment.
- People whose life expectancy is at least 3 months.
- People whose blood and other lab test results meet the required levels at the screening visit (confirm with trial site for specific values).
- People whose heart, liver, kidneys, and other organs are functioning well enough to meet the trial's requirements (confirm with trial site for specific criteria).
Who may not be able to join:
- People who have recently received other cancer treatments and have not waited long enough since finishing them (confirm with trial site for specific timeframes).
- People who have previously received a treatment that targeted a protein called GPRC5D.
- People who test positive for hepatitis B, hepatitis C, or HIV.
- People with a known serious allergic reaction or intolerance to any ingredient in the study drug, including a substance called DMSO, or people who have a history of severe allergic reactions that required strong medicines such as steroids to manage.
- People whose overall health situation is considered by the trial doctor to make participation unsuitable for any reason.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 025-68306091
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence, severity and type of TEAEs (Treatment-emergent Adverse Events); Pharmacokinetics in peripheral blood; Pharmacokinetics in bone marrow; The recommended Phase II dose (RP2D) for this cell
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.